How the Liver Processes THC From Cannabis

When THC enters your body, the liver acts as the central processing hub, converting it into new compounds, some of them more psychoactive than THC itself. The specific enzymes involved, how much THC survives the liver’s first crack at it, and how quickly the whole process happens vary depending on whether you smoked, vaped, or ate the cannabis. That variability in liver processing is the main reason a 10-milligram edible can floor someone while a similar dose inhaled feels mild and short-lived.

What the Liver Does When THC Shows Up

THC is fat-soluble and doesn’t dissolve easily in blood, so the body treats it like a foreign substance to be broken down and excreted. When you inhale cannabis, THC crosses from the lungs directly into the bloodstream and reaches the brain within minutes. Peak blood levels arrive in about six to ten minutes. Some of that circulating THC eventually passes through the liver, where it gets metabolized, but a good chunk has already done its work in the brain before the liver even sees it. The bioavailability of inhaled THC is roughly 10 to 35 percent.

1PubMed Central. Mechanisms of Action and Pharmacokinetics of Cannabis

Edibles take a completely different path. THC is absorbed from the gut into the bloodstream and funneled directly to the liver through the portal vein before it ever reaches the rest of your body. This is called first-pass metabolism, and it’s aggressive. The liver converts most of the THC before it can circulate, which is why the bioavailability of eaten THC drops to roughly 4 to 12 percent.

1PubMed Central. Mechanisms of Action and Pharmacokinetics of Cannabis

But here’s where it gets interesting: the liver doesn’t just destroy THC. It converts a large portion of it into a metabolite called 11-hydroxy-THC (11-OH-THC), which is psychoactive, crosses the blood-brain barrier easily, and is arguably more potent than THC itself. With edibles, 11-OH-THC appears in the blood in higher amounts than when you smoke the same dose of THC, which likely explains why edible highs tend to feel stronger and last longer.

2PubMed Central. Tasty THC: Promises and Challenges of Cannabis Edibles

The Enzymes That Do the Heavy Lifting

The liver breaks down THC using a family of enzymes called the cytochrome P450 system. These enzymes handle the metabolism of a huge range of drugs and toxins, not just cannabinoids. For THC, one enzyme in particular does most of the work: CYP2C9. This enzyme is responsible for the main clearance pathway, converting THC into 11-OH-THC. Estimates put CYP2C9’s share of total THC breakdown at around 80 to 90 percent.

3Drug Metabolism and Disposition. Hepatic Enzymes Relevant to the Disposition of (−)-∆9-Tetrahydrocannabinol (THC) and Its Psychoactive Metabolite, 11-OH-THC4Drug Metabolism and Disposition. Quantifying Hepatic Enzyme Kinetics of (-)-Δ9-Tetrahydrocannabinol (THC) and Its Psychoactive Metabolite, 11-OH-THC, through In Vitro Modeling

A second group of enzymes, CYP3A4 and CYP3A5, handles a different set of reactions. Rather than creating 11-OH-THC, these enzymes tend to add oxygen at other positions on the THC molecule, producing metabolites that are mostly inactive. CYP2C19 also pitches in as a minor contributor to the 11-OH-THC pathway.

5PubMed. Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes6PubMed Central. CYP2C9, CYP3A and CYP2C19 metabolize Δ9-tetrahydrocannabinol to multiple metabolites but metabolism is affected by human liver fatty acid binding protein (FABP1)

So the liver isn’t doing one thing to THC. It’s running multiple reactions simultaneously, with CYP2C9 generating the psychoactive metabolite and CYP3A4 generating mostly inert byproducts. The balance between these pathways matters for how intense and long the high feels.

From Active Metabolite to Something Your Body Can Excrete

After 11-OH-THC is formed, the liver oxidizes it further into THC-COOH (11-nor-9-carboxy-THC), which is no longer psychoactive. THC-COOH is the metabolite that drug tests detect in urine, and it can linger in the body for days or weeks because it gets stored in fat tissue. But THC-COOH itself still isn’t water-soluble enough to be flushed out easily. The liver runs a second round of processing, called glucuronidation, in which a different set of enzymes attaches a sugar molecule to THC-COOH. The resulting compound, a glucuronide, is water-soluble and can finally be excreted in urine.

7Drug Metabolism and Disposition. Characterization of Human Hepatic and Extrahepatic UDP-Glucuronosyltransferase Enzymes Involved in the Metabolism of Classic Cannabinoids

Not all of it goes out through the kidneys, though. A significant portion of THC metabolites are excreted into bile and dumped into the small intestine, where some get reabsorbed back into the bloodstream and sent to the liver again. This loop, called enterohepatic recirculation, is one reason THC metabolites can stay detectable in the body much longer than you’d expect from the initial dose. The recirculation also helps explain the secondary peaks in blood THC levels that sometimes show up hours after use.

8PubMed. Distribution of free and conjugated cannabinoids in human bile samples9Scientific Reports. Pharmacokinetics and central accumulation of delta-9-tetrahydrocannabinol (THC) and its bioactive metabolites are influenced by route of administration and sex in rats

Why Some People Process THC Faster Than Others

Because CYP2C9 handles most of the THC breakdown, genetic variants in the gene coding for that enzyme can meaningfully shift how your body handles cannabis. The most studied variant is CYP2C9*3. People who carry two copies of this slow-function variant showed a roughly threefold higher THC exposure (measured as area under the curve) after an oral dose compared to people with the normal version. At the same time, their levels of the downstream metabolite THC-COOH were about 70 percent lower, consistent with the enzyme working much less efficiently. They also trended toward more sedation.

10PubMed. Interindividual variation in the pharmacokinetics of Delta9-tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9

A separate study looking at blood samples from suspected impaired drivers confirmed that carriers of the CYP2C9*3 variant had significantly lower THC-COOH concentrations and a higher ratio of THC to THC-COOH. That ratio matters in forensic settings because it’s used to estimate how recently someone consumed cannabis. A person with a slow-function CYP2C9 variant might look like a more recent user on paper even though they consumed the same amount at the same time as someone with normal enzyme activity.

11International Journal of Legal Medicine. Toxicogenetic analysis of Δ9-THC-metabolizing enzymes

Sex may add another layer. One study found that among male cannabis users, normal metabolizers reported fewer early negative effects (anxiety, paranoia) than slow metabolizers, while that pattern didn’t hold for women. The sample was small and exploratory, but all female slow metabolizers in the study met criteria for cannabis use disorder, compared to about a third of male slow metabolizers.

12PubMed Central. Evidence for Sex Differences in the Impact of Cytochrome P450 Genotypes on Early Subjective Effects of Cannabis

Drug Interactions Worth Knowing About

Because THC and CBD are both processed by and can inhibit cytochrome P450 enzymes, they have the potential to alter how your body handles other drugs metabolized by the same pathways. THC and CBD are substrates of, and inhibitors of, CYP enzymes relevant to many commonly prescribed medications, including some psychiatric drugs, blood thinners, and anti-seizure medications.

13PubMed. Drug-drug interactions as a result of co-administering Δ9-THC and CBD with other psychotropic agents

CBD deserves special attention here because it’s a much stronger inhibitor of CYP3A4 and CYP3A5 than THC is. In lab studies, CBD blocked CYP3A4 activity at concentrations far lower than what it took for THC to have the same effect.

14PubMed. Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety

CYP3A4 is responsible for metabolizing a huge range of prescription drugs. If CBD is slowing it down, those drugs may build up to higher levels in your blood than expected. This is the same reason grapefruit juice carries warnings with certain medications. Anyone using cannabis products alongside prescription drugs, particularly high-dose CBD products, should be aware that interactions are plausible and potentially clinically relevant.

15PubMed Central. Evaluation of potential drug-drug interactions with medical cannabis

How Food and Fat Change the Picture

Cannabinoids are lipophilic, meaning they dissolve in fats, not water. When you eat THC or CBD with a high-fat meal, the fat helps carry the cannabinoid into the lymphatic system via particles called chylomicrons. This pathway partially bypasses the liver’s first-pass metabolism, because lymphatic absorption dumps into the bloodstream without going through the portal vein first. Research on CBD specifically found that roughly a third of an administered dose was taken up into the fat-processing layer of the gut when given with lipids.

16Scientific Reports. A high-fat meal significantly impacts the bioavailability and biphasic absorption of cannabidiol (CBD) from a CBD-rich extract in men and women

The type of fat even matters. In an animal study comparing different vegetable oils as carriers for oral CBD, olive oil produced the highest concentrations of CBD both in the lymphatic system and in general circulation.

17PubMed. Vegetable oils composition affects the intestinal lymphatic transport and systemic bioavailability of co-administered lipophilic drug cannabidiol

For practical purposes, this means that taking an edible on an empty stomach versus with a fatty meal can produce substantially different experiences. The fatty meal doesn’t just improve absorption; it can shift which metabolic pathway the cannabinoid primarily enters. This is why dosing advice for pharmaceutical cannabinoids sometimes specifies whether to take them with or without food.

Sex Differences in THC Metabolism

Rat studies have consistently shown that female and male livers handle THC differently. In female rats, the liver converts THC predominantly into the active metabolite 11-OH-THC, while male rat livers spread the metabolism across a wider array of mostly inactive products. Female adolescent rats showed this pattern even more strongly than adult females, with particularly high brain concentrations of 11-OH-THC after repeated dosing.

18PubMed Central. Sex Differences in Δ9-Tetrahydrocannabinol Metabolism and In Vivo Pharmacology Following Acute and Repeated Dosing in Adolescent Rats

Earlier work confirmed this at the enzyme level: female rat liver microsomes oxidized THC selectively to 11-OH-THC, while male rat liver microsomes produced a broader panel of metabolites including several hydroxylated forms.

19Biochemical Pharmacology. Sex difference in the oxidative metabolism of Δ9-tetrahydrocannabinol in the rat

These are rat findings, and translating rodent liver metabolism directly to humans is always uncertain. But the direction is suggestive: if a similar pattern holds in people, women might produce more of the potent metabolite per unit of THC consumed, which could contribute to the sex differences in cannabis sensitivity that clinicians and users have noticed anecdotally. Human studies in this specific area remain thin.

Aging and Liver Capacity

Liver function declines with age. Blood flow to the liver decreases, liver mass shrinks, and the overall activity of metabolizing enzymes tends to slow. For cannabinoids, this means older adults may break down THC and CBD more slowly, leading to higher blood concentrations from the same dose. When you layer genetic variation on top of age-related decline, the potential for unexpectedly strong effects grows. An older person who happens to carry a slow-function CYP2C9 variant could experience substantially more intense or prolonged effects from a standard dose.

20HigherGov. Quantifying Effects of Comorbidities and Genetics on Cannabinoid Exposure in the Elderly

This isn’t just theoretical. As cannabis use among adults over 65 has risen steeply in recent years, clinicians have increasingly encountered older patients with adverse reactions to doses that younger users tolerate easily. The pharmacokinetic explanation is straightforward: a liver that is slower at clearing a drug produces higher peaks and longer durations of effect.

CBD and the Question of Liver Harm

While THC gets most of the attention in discussions about cannabis and the liver, the evidence for actual liver injury has been accumulating more around CBD, particularly at the high doses used to treat epilepsy. A randomized trial in healthy adults found that about 5.6 percent of participants receiving CBD developed liver enzyme elevations exceeding three times the upper limit of normal after four weeks, compared to zero in the placebo group.

21JAMA Internal Medicine. Cannabidiol and Liver Enzyme Level Elevations in Healthy Adults: A Randomized Clinical Trial

A systematic review pooling data from 12 trials found that CBD use was associated with roughly six times the odds of liver enzyme elevation compared to placebo. About 7 percent of participants taking CBD developed elevated enzymes, and about 3 percent met criteria for drug-induced liver injury. The strongest risk factors were high doses (at or above 1,000 milligrams per day or 20 milligrams per kilogram per day) and simultaneous use of anti-epileptic drugs that compete for the same liver enzymes.

22Journal of Internal Medicine. Cannabidiol‐associated hepatotoxicity: A systematic review and meta‐analysis

For context, the CBD doses associated with liver injury are far above what most people take as a wellness supplement. Prescription CBD for epilepsy can reach 20 mg/kg/day, which for a 70-kilogram adult is 1,400 milligrams daily. Most over-the-counter CBD products deliver 25 to 50 milligrams per serving. Still, the finding matters because it underscores that the liver is doing real biochemical work when processing cannabinoids, and overloading those pathways has consequences.

THC Crossing the Placenta

Pregnancy adds another dimension to liver processing of THC. Both THC and its active metabolite 11-OH-THC can cross the placenta and reach the fetal brain. Modeling research has predicted that at a daily inhaled dose of 10 milligrams of THC around week 15 of pregnancy, THC concentrations in fetal brain tissue are measurable, and 11-OH-THC levels in fetal brain may actually exceed THC levels there. With oral consumption of the same dose, the fetal brain’s THC concentration drops but the 11-OH-THC concentration stays comparable, because the mother’s liver has converted so much THC into the active metabolite before it circulates.

23Nature Communications. Quantification and prediction of human fetal (-)-Δ9-tetrahydrocannabinol/(±)-11-OH-Δ9-tetrahydrocannabinol exposure during pregnancy to inform fetal cannabis toxicity

The concentrations predicted in fetal tissue are low in absolute terms, but the fetal brain is developing rapidly and may be sensitive to even small exposures. The modeling also suggested that fetal exposure increases as pregnancy progresses because placental blood flow rises. Research on the long-term consequences of prenatal cannabinoid exposure is still catching up with the rates of cannabis use during pregnancy, which have increased considerably in the last decade.